Journals / Klimik Dergisi / 2018 / Cilt: 31 - Sayı: 2

Determination of the Differences in Penetration of Tigecycline and Vancomycin Into Bronchial Epithelium of Normal and Cystic Fibrosis Lung

Tigesiklin ve Vankomisinin Normal ve Kistik Fibrozlu Akciğerin Bronş Epiteline Girişleri Arasındaki Farkın Belirlenmesi

Pages
139–143
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These data suggest that tigecycline has a high therapeutic potential in lung infections of patients with cystic fibrosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to investigate the dose and time course of tigecycline and vancomycin for effective intracellular concentration in bronchial epithelium of normal and cystic fibrosis lung.
📊
Key Findings & Data:Methods: Differences between vancomycin and tigecycline in terms of their dose- and time-dependent intracellular concentrations were determined with in vitro cell culture and the high performance liquid chromatography techniques.
💡
Conclusion & Impact:These data suggest that tigecycline has a high therapeutic potential in lung infections of patients with cystic fibrosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to investigate the dose and time course of tigecycline and vancomycin for effective intracellular concentration in bronchial epithelium of normal and cystic fibrosis lung. Methods: Differences between vancomycin and tigecycline in terms of their dose- and time-dependent intracellular concentrations were determined with in vitro cell culture and the high performance liquid chromatography techniques. Results: The penetration of tigecycline was found significantly higher in cystic fibrosis cells compared to normal bronchial cells. The optimal dose for tigecycline was 30 μg/mL and the optimal time was 8 h in comparison to given dose and penetrating amount into the cells. Vancomycin dose needed to be given for minimal penetration into the cell was extremely higher than the minimum inhibitor concentration described in the guidelines. Conclusions: Penetration of tigecycline into cells of cystic fibrosis lung was found higher than normal lung cells, whereas cell penetration of vancomycin into both normal and cystic fibrosis cells was limited. These data suggest that tigecycline has a high therapeutic potential in lung infections of patients with cystic fibrosis.

Özet

Amaç: Bu çalışmada normal ve kistik fibrozlu bronş epitelindetigesiklin ve vankomisinin ulaşabileceği etkin hücre içi konsantrasyonların,doz ve zaman parametrelerine bağlı olarak araştırılmasıamaçlanmıştır.Yöntemler: Tigesiklin ve vankomisin arasındaki doz ve zamanabağlı hücre içi konsantrasyonları yönünden farklılıklar, hücrekültürü ve yüksek performanslı sıvı kromatografisiyle belirlenmiştir.Bulgular: Tigesiklinin kistik fibrozlu bronş epiteline girişiylenormal hücreye girişi arasındaki farkın, anlamlı olarak yüksekolduğu bulunmuştur. Hücre içine giren miktar, uygulanan dozlarlakarşılaştırıldığında, hücre içine optimal girişin olduğu doz30 μg/ml, zaman ise 8 saat olarak tespit edilmiştir. Vankomisininhücre içine minimal miktarda girebilmesi için, kılavuzlardabelirtilen minimum inhibitör konsantrasyonun çok üstündekidozlarda vermek gerektiği tespit edilmiştir.Sonuçlar: Tigesiklinin kistik fibrozlu bronş epiteline girişi normalbronş epiteline oranla daha yüksek bulunmuştur. Vankomisininkistik fibrozlu ve normal bronş epiteline girişinin ise yokdenecek kadar az olduğu tespit edilmiştir. Bu nedenle, tigesiklininkistik fibrozlu hastaların akciğer infeksiyonlarında yüksekbir terapötik potansiyeli olduğu düşünülmüştür.

🔖

Cite This Article

GÖKBULUT, C., SAKARYA, S., GÜNAY, N., AKAR, F. (2022). Determination of the Differences in Penetration of Tigecycline and Vancomycin Into Bronchial Epithelium of Normal and Cystic Fibrosis Lung. Klimik Dergisi, Cilt: 31 - Sayı: 2, 139–143. https://ajindex.com/articles/573518

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Guggino WB. Cystic fibrosis salt/fluid controversy: in the thick of it. Nat Med. 2001; 7(8): 888-9. [CrossRef] 2. Verkman AS. Lung disease in cystic fibrosis: is airway surface liquid composition abnormal? Am J Physiol Lung Cell Mol Physiol. 2001; 281(2): L306-8. [CrossRef] 3. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998; 95(7): 1005-15. [CrossRef] 4. Puchelle E, de Bentzmann S, Zahm JM. Physical and functional properties of airway secretions in cystic fibrosis--therapeutic approaches. Respiration. 1995; 62(Suppl. 1): 2-12. [CrossRef] 5. Accurso FJ, Sontag MK. Gene modifiers in cystic fibrosis. J Clin Invest. 2008; 118(3): 839-41. [CrossRef] 6. Kristidis P, Bozon D, Corey M, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet. 1992; 50(6): 1178-84. 7. Savant AP, McColley SA. Cystic fibrosis year in review 2016. Pediatr Pulmonol. 2017; 52(8): 1092-102. [CrossRef] 8. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002; 15(2): 194-222. [CrossRef] 9. Tarran R, Grubb BR, Parsons D, et al. The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell. 2001; 8(1): 149-58. [CrossRef] 10. Matsui H, Randell SH, Peretti SW, Davis CW, Boucher RC. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Invest. 1998; 102(6): 1125-31. [CrossRef] 11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. CLSI Document M100-S18.Wayne, PA: Clinical and Laboratory Standards Institute, 2008. 12. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 6.0, Valid From 2016-01-01 [İnternet]. Basel, Switzerland: European Committee on Antimicrobial Susceptibility Testing (EUCAST) [erişim 1 Ocak 2018]. http://www.eu- cast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_ tables/v_6.0_Breakpoint_table.xls 13. Kitzman D, Cheng KJ, Fleckenstein L. HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. J Pharm Biomed Anal. 2002; 30(3): 801-13. [CrossRef] 14. Li C, Sutherland CA, Nightingale CH, Nicolau DP. Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 811(2):